CSL’s Flu Vaccine Aims For China Market
This article was originally published in PharmAsia News
Executive Summary
CSL Biotherapies announced that following last September's FDA approval of its split virion flu vaccine, it has submitted an application to China's State FDA to bring the vaccine to China. To be sold under the brand Fluvax, it is likely to be introduced during the 2008-09 flu season. Experts point out that the local population still lack understanding of the importance of flu prevention, especially during an epidemic. However, with increasing awareness, the public demand for such vaccines is growing. The influx of international drug companies, which bring in the latest products and experience for preventing the disease, also helps to raise local awareness. (Click here for more - Chinese Language)